<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974073</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH106-REC3-028</org_study_id>
    <nct_id>NCT04974073</nct_id>
  </id_info>
  <brief_title>Development of PHY606 as Adjunct Therapy for Anemia Patients</brief_title>
  <official_title>Development of PHY606 as Adjunct Therapy for Anemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheng-Teng Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many reasons can cause anemia, decreased RBC production or increased destruction of&#xD;
      circulation RBC. The investigators investigate the Danggui Buxue Tang (PHY606) composed of&#xD;
      Angelicae Sinensis Radix and Astragali Radix in the fields of genomic and metabolomics in the&#xD;
      healthy people and the patiens with anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many reasons can cause anemia, decreased RBC production or increased destruction of&#xD;
      circulating RBC. The reasons of the former are lake of nutrients, bone marrow disorder, low&#xD;
      level tropic hormone, inflammation associated with infectious, inflammatory, or malignant&#xD;
      disorders and the latter are intravascular hemolysis or blood loss. Anemia is characterized&#xD;
      by the sign of pallor (reduced oxyhemoglobin in skin or mucous membranes), fatigue,&#xD;
      lightheadedness, and weakness associated with low hemoglobin.&#xD;
&#xD;
      Iron deficiency anemia (IDA) is mainly resulted from inadequate iron uptake of food,&#xD;
      malabsorption of iron and blood loss. Adult female are easy to have IDA compared to male&#xD;
      because of menstruation, pregnancy, lactation and low caloric uptake leading to iron&#xD;
      deficiency. In Taiwan, cancer-related and chronic kidney disease also lead to insufficient&#xD;
      secretion of erythropoietin (EPO). The cost of long-term use EPO and its derivative drugs is&#xD;
      high. Besides, drug resistance, risk of tumor growth and cardiovascular disease are all&#xD;
      important issues. However, ferrotherapy will induce GI upset, muscle pain and skin hives.&#xD;
      Also, iron supplementation can lead to an increase in infectious disease morbidity in areas&#xD;
      where bacterial infections or where malaria are common.&#xD;
&#xD;
      Based on the concept of dietetic invigoration, the investigators investigate the Danggui&#xD;
      Buxue Tang (PHY606) composed of Angelicae Sinensis Radix and Astragali Radix in the fields of&#xD;
      genomics and metabolomics in the healthy people and the patients with anemia. In the&#xD;
      meantime, the investigators will explore whether PHY606 activates the immune function,&#xD;
      improves anemia and reduces the side effects induced by anemia treatment. Furthermore, the&#xD;
      novel metabolites from Angelicae Sinensis Radix and Astragali Radix will be tested from&#xD;
      clinic back to the bench including immunological potentiation and hematopoietic function.&#xD;
      According to the TCM theory, the investigators integrate with modern medicine and molecular&#xD;
      biotechnology to investigate anemia and hope to provide the evidence base for clinical&#xD;
      application.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Actual">November 18, 2019</completion_date>
  <primary_completion_date type="Actual">August 22, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Constitution in Chinese Medicine Questionnaire (CCMQ)</measure>
    <time_frame>Change from baseline CCMQ at Day0, Day31, Day93 and Day180.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Cytokines</measure>
    <time_frame>Change from baseline serum cytokines at Day0, Day31 and Day93.</time_frame>
    <description>Collect blood and measure the level of serum cytokines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tongue diagnosis</measure>
    <time_frame>Change from baseline tongue diagnosis at Day0 and Day93.</time_frame>
    <description>Use tongue photos for analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse diagnosis</measure>
    <time_frame>Change from baseline Pulse diagnosis at Day0 and Day93.</time_frame>
    <description>Use the pulse detector to detect the rhythm data of the subject's left and right hand pulse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia blood test</measure>
    <time_frame>Change from baseline anemia blood at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the level of ferritin(ng/mL), TIBC(ug/dL), transferrin(mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotype</measure>
    <time_frame>Change from baseline genotype at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and analyze the genotype by microarray assay.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)</measure>
    <time_frame>Change from baseline FACIT-F score at Day0, Day31, Day93 and Day180.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Change from baseline PSQI score at Day0, Day31, Day93 and Day180.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>Change from baseline SF-36 score at Day0, Day31, Day93 and Day180.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>White blood cell (WBC)</measure>
    <time_frame>Change from baseline WBC at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of WBC (x 10^3/ul).</description>
  </other_outcome>
  <other_outcome>
    <measure>Red Blood Cells (RBC)</measure>
    <time_frame>Change from baseline RBC at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of RBC (x 10^6/ul).</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin (Hb)</measure>
    <time_frame>Change from baseline Hemoglobin at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of Hemoglobin (gm/dL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Hematocrit (Hct)</measure>
    <time_frame>Change from baseline Hematocrit at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of Hematocrit (%).</description>
  </other_outcome>
  <other_outcome>
    <measure>Red blood cell volume distribution width (RDW)</measure>
    <time_frame>Change from baseline RDW at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of RDW (%).</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelet</measure>
    <time_frame>Change from baseline Platelet at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of Platelet (x 10^3/ul).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean corpuscular volume (MCV)</measure>
    <time_frame>Change from baseline MCV at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of MCV (fl).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean corpuscular hemoglobin (MCH)</measure>
    <time_frame>Change from baseline MCH at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of MCH (pg).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean corpuscular hemoglobin concentration (MCHC)</measure>
    <time_frame>Change from baseline MCHC at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of MCHC (g/dL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean platelet volume (MPV)</measure>
    <time_frame>Change from baseline MPV at Day 0, Day 31 and Day93.</time_frame>
    <description>Collect blood and measure the value of MPV (fl).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Anemia</condition>
  <condition>Herbal Interaction</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>with traditional western medicine treatment based on underlined disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHY606</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHY606 7.5gm BID for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PHY606 7.5gm BID for 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHY606</intervention_name>
    <description>Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism</description>
    <arm_group_label>Healthy group</arm_group_label>
    <arm_group_label>PHY606</arm_group_label>
    <other_name>Danggui Buxue Tang</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female: Hb&lt;11 g/dL; male: Hb&lt;13.5 g/dL&#xD;
&#xD;
          -  has no allergic reaction to TCM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  below 20 years old&#xD;
&#xD;
          -  ever drug abuse or still in drug abuse&#xD;
&#xD;
          -  pregnant or in breast-feeding women&#xD;
&#xD;
          -  with psychotic disorders&#xD;
&#xD;
          -  cardiac arrhythmia with pacemaker&#xD;
&#xD;
          -  dyscoagulation or thrombocytopenia (platelet&lt; 15000/uL) or liver dysfunction (&gt; 2 fold&#xD;
             normal range)&#xD;
&#xD;
          -  with severe disease (cardiac arrest, heart failure, COPD, GI bleeding, etc.)&#xD;
&#xD;
          -  under another clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheng-Teng Huang, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University Hospital</investigator_affiliation>
    <investigator_full_name>Sheng-Teng Huang</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Danggui Buxue Tang</keyword>
  <keyword>PHY606</keyword>
  <keyword>Side effects</keyword>
  <keyword>TCM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

